Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102387 | 0.92 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL13102397 | 0.92 | TRPV1 (0.41) | SMN1; SMN2ALDH1A1TSHRLMNAATM | |
| SCHEMBL13102245 | 0.92 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL13102386 | 0.92 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL13102396 | 0.91 | TRPV1 (0.45) | SMN1; SMN2ALDH1A1TSHRATMNR1H2 | |
| SCHEMBL3180841 | 0.90 | P2RX7 (0.41) | SMN1; SMN2ALDH1A1TSHRATMTRPA1 | |
| SCHEMBL13102187 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL13102473 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL13102088 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL13102393 | 0.86 | TRPV1 (0.46) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885ALDH1A1 2354/4885TSHR 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.